Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
AtriCure (ATRC) Reports Break-Even Earnings for Q1
06:16pm, Tuesday, 05'th May 2026
AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
AtriCure Reports First Quarter 2026 Financial Results
04:01pm, Tuesday, 05'th May 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
08:00am, Tuesday, 28'th Apr 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts
10:10pm, Sunday, 26'th Apr 2026
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 20
AtriCure to Announce First Quarter 2026 Financial Results
08:00am, Tuesday, 14'th Apr 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
04:06pm, Wednesday, 18'th Mar 2026
ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 at around $29.83 per share on March 12, 2026. The sale represented 4.91% of Vinayak's direct holdings
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Analysts
02:10am, Tuesday, 10'th Mar 2026
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One an
Citigroup Inc. Purchases 36,839 Shares of AtriCure, Inc. $ATRC
03:36am, Monday, 09'th Mar 2026
Citigroup Inc. raised its position in AtriCure, Inc. (NASDAQ: ATRC) by 182.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (
AtriCure to Participate in the Citizens Life Sciences Conference
08:00am, Tuesday, 24'th Feb 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure Q4 Earnings Call Highlights
04:06am, Thursday, 19'th Feb 2026
AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
08:00pm, Tuesday, 17'th Feb 2026
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
07:24pm, Tuesday, 17'th Feb 2026
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates
06:36pm, Tuesday, 17'th Feb 2026
AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
04:01pm, Tuesday, 17'th Feb 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure (NASDAQ:ATRC) Shares Gap Down Following Analyst Downgrade
02:38am, Thursday, 12'th Feb 2026
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) gapped down before the market opened on Wednesday after JPMorgan Chase and Co. downgraded the stock from an overweight rating to a neutral rating. The s
